Recurrent Solid Neoplasm Suspended Phase 2 Trials for DB01590 (Everolimus)

IndicationStatusPhase
DBCOND0080814 (Recurrent Solid Neoplasm)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01827384Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid TumorsTreatment